Terms: = Breast cancer AND Neurokinin AND Treatment
46 results:
1. Harnessing the synergistic potential of NK1R antagonists and selective COX-2 inhibitors for simultaneous targeting of TNBC cells and cancer stem cells.
Singh MT; Thaggikuppe Krishnamurthy P; Magham SV
J Drug Target; 2024 Dec; 32(3):258-269. PubMed ID: 38252517
[TBL] [Abstract] [Full Text] [Related]
2. Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms.
Sassarini J; Anderson RA
Expert Opin Investig Drugs; 2024 Jan; 33(1):19-26. PubMed ID: 38224099
[TBL] [Abstract] [Full Text] [Related]
3. Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase.
Inui N; Toi Y; Yoneshima Y; Morise M; Hata A; Kubota K; Saeki T; Tamura T
Adv Ther; 2023 Nov; 40(11):4928-4944. PubMed ID: 37715851
[TBL] [Abstract] [Full Text] [Related]
4. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.
Chiu JWY; Lee SC; Ho JC; Park YH; Chao TC; Kim SB; Lim E; Lin CH; Loi S; Low SY; Teo LLS; Yeo W; Dent R
Drug Saf; 2023 Oct; 46(10):927-949. PubMed ID: 37552439
[TBL] [Abstract] [Full Text] [Related]
5. New advances in menopause symptom management.
Koysombat K; McGown P; Nyunt S; Abbara A; Dhillo WS
Best Pract Res Clin Endocrinol Metab; 2024 Jan; 38(1):101774. PubMed ID: 37076317
[TBL] [Abstract] [Full Text] [Related]
6. Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective.
Abe M; Iihara H; Aogi K
Adv Ther; 2023 May; 40(5):1913-1925. PubMed ID: 36884027
[TBL] [Abstract] [Full Text] [Related]
7. Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity.
Kabil MF; Mahmoud MY; Bakr AF; Zaafar D; El-Sherbiny IM
Life Sci; 2022 Sep; 305():120731. PubMed ID: 35753435
[TBL] [Abstract] [Full Text] [Related]
8. Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B).
Ozeki R; Iihara H; Shimokawa M; Hashimoto H; Abe M; Mukohara T; Bando H; Hayashi T; Kawazoe H; Komoda M; Yanai Takahashi T; Saito M
BMJ Open; 2022 Mar; 12(3):e058755. PubMed ID: 35236735
[TBL] [Abstract] [Full Text] [Related]
9. Impact of the Oncology Care Model on Use of Supportive Care Medications During cancer treatment.
Brooks GA; Landrum MB; Kapadia NS; Liu PH; Wolf R; Riedel LE; Hsu VD; Jhatakia Parekh S; Simon C; Hassol A; Keating NL
J Clin Oncol; 2022 Jun; 40(16):1763-1771. PubMed ID: 35213212
[TBL] [Abstract] [Full Text] [Related]
10. A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC.
Matsuura K; Tsurutani J; Inoue K; Tanabe Y; Taira T; Kubota K; Tamura T; Saeki T
Cancer; 2022 Apr; 128(8):1692-1698. PubMed ID: 35045185
[TBL] [Abstract] [Full Text] [Related]
11. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.
Hata A; Okamoto I; Inui N; Okada M; Morise M; Akiyoshi K; Takeda M; Watanabe Y; Sugawara S; Shinagawa N; Kubota K; Saeki T; Tamura T
J Clin Oncol; 2022 Jan; 40(2):180-188. PubMed ID: 34793245
[TBL] [Abstract] [Full Text] [Related]
12. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
[TBL] [Abstract] [Full Text] [Related]
13. neurokinin 3 receptor antagonists - prime time?
Prague JK
Climacteric; 2021 Feb; 24(1):25-31. PubMed ID: 33135940
[TBL] [Abstract] [Full Text] [Related]
14. [Hot flushes and breast cancer with positive hormone receptors: Mechanisms and management].
Cavadias I; Rouzier R; Lerebours F; Héquet D
Bull Cancer; 2020 Nov; 107(11):1171-1185. PubMed ID: 32988609
[TBL] [Abstract] [Full Text] [Related]
15. TGFβ regulates NK1R-Tr to affect the proliferation and apoptosis of breast cancer cells.
Wang L; Wang N; Zhang R; Dong D; Liu R; Zhang L; Ji W; Yu M; Zhang F; Niu R; Zhou Y
Life Sci; 2020 Sep; 256():117674. PubMed ID: 32380077
[TBL] [Abstract] [Full Text] [Related]
16. NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences.
Nizam E; Köksoy S; Erin N
Cancer Immunol Immunother; 2020 Aug; 69(8):1639-1650. PubMed ID: 32322911
[TBL] [Abstract] [Full Text] [Related]
17. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with breast cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
Schwartzberg L; Navari R; Clark-Snow R; Arkania E; Radyukova I; Patel K; Voisin D; Rizzi G; Wickham R; Gralla RJ; Aapro M; Roeland E
Oncologist; 2020 Mar; 25(3):e589-e597. PubMed ID: 32162813
[TBL] [Abstract] [Full Text] [Related]
18. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
Iihara H; Shimokawa M; Hayashi T; Kawazoe H; Saeki T; Aiba K; Tamura K
Oncologist; 2020 Feb; 25(2):e373-e380. PubMed ID: 32043774
[TBL] [Abstract] [Full Text] [Related]
19. Triple Negative breast cancer: How neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach.
Muñoz M; Rosso M; Coveñas R
Mini Rev Med Chem; 2020; 20(5):408-417. PubMed ID: 31721701
[TBL] [Abstract] [Full Text] [Related]
20. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Navari RM
Expert Opin Drug Saf; 2020 Feb; 19(2):205-210. PubMed ID: 31709853
[No Abstract] [Full Text] [Related]
[Next]